{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:31:10Z","timestamp":1778895070063,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health","award":["T32 AI155385"],"award-info":[{"award-number":["T32 AI155385"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-022-08952-y","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T09:04:12Z","timestamp":1662023052000},"page":"381-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-2539","authenticated-orcid":false,"given":"Benjamin","family":"Greiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savannah","family":"Nicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Adame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"12","key":"8952_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F et al (2017) The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 72(12):2005\u20132016. https:\/\/doi.org\/10.1111\/all.13209","journal-title":"Allergy"},{"issue":"2","key":"8952_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J, \u00c1vila G, Keller T et al (2020) Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 75(2):423\u2013432. https:\/\/doi.org\/10.1111\/all.14037","journal-title":"Allergy"},{"issue":"6","key":"8952_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/pai.12910","volume":"29","author":"MM Balp","year":"2018","unstructured":"Balp MM, Weller K, Carboni V et al (2018) Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol 29(6):630\u2013636. https:\/\/doi.org\/10.1111\/pai.12910","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"8952_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaip.2018.04.013","volume":"6","author":"SS Saini","year":"2018","unstructured":"Saini SS, Kaplan AP (2018) Chronic spontaneous urticaria: the devil\u2019s itch. J Allergy Clin Immunol Pract 6(4):1097\u20131106. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.013","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"8952_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/09546634.2016.1246705","volume":"28","author":"VK Sharma","year":"2017","unstructured":"Sharma VK, Gupta V, Pathak M, Ramam M (2017) An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatol Treat 28(6):539\u2013543. https:\/\/doi.org\/10.1080\/09546634.2016.1246705","journal-title":"J Dermatol Treat"},{"issue":"4","key":"8952_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.18176\/jiaci.0649","volume":"31","author":"P Iriarte Sot\u00e9s","year":"2021","unstructured":"Sot\u00e9s PI, Armis\u00e9n M, Usero-B\u00e1rcena T et al (2021) Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: a systematic review of the literature. J Investig Allergol Clin Immunol 31(4):282\u2013291. https:\/\/doi.org\/10.18176\/jiaci.0649","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"8952_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M et al (2022) The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77(3):734\u2013766. https:\/\/doi.org\/10.1111\/all.15090","journal-title":"Allergy"},{"issue":"5","key":"8952_CR8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","volume":"133","author":"JA Bernstein","year":"2014","unstructured":"Bernstein JA, Lang DM, Khan DA et al (2014) The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 133(5):1270\u20131277. https:\/\/doi.org\/10.1016\/j.jaci.2014.02.036","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8952_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.alit.2018.09.006","volume":"68","author":"T Endo","year":"2019","unstructured":"Endo T, Toyoshima S, Kanegae K et al (2019) Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria. Allergol Int 68(2):270\u2013273. https:\/\/doi.org\/10.1016\/j.alit.2018.09.006","journal-title":"Allergol Int"},{"issue":"7","key":"8952_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.jaip.2020.03.022","volume":"8","author":"G Sussman","year":"2020","unstructured":"Sussman G, H\u00e9bert J, Gulliver W et al (2020) Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial. J Allergy Clin Immunol Pract 8(7):2372-2378.e5. https:\/\/doi.org\/10.1016\/j.jaip.2020.03.022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"8952_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M et al (2013) Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 132(1):101\u2013109. https:\/\/doi.org\/10.1016\/j.jaci.2013.05.013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8952_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.anai.2018.06.014","volume":"121","author":"E Nettis","year":"2018","unstructured":"Nettis E, Cegolon L, Di Leo E et al (2018) Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol 121(4):474\u2013478. https:\/\/doi.org\/10.1016\/j.anai.2018.06.014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"8952_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","volume":"18","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA, Kavati A, Tharp MD et al (2018) Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u201creal-world\u201d evidence. Expert Opin Biol Ther 18(4):425\u2013448. https:\/\/doi.org\/10.1080\/14712598.2018.1438406","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"8952_CR14","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJMc2016395","volume":"383","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D (2020) Benralizumab for chronic spontaneous urticaria. N Engl J Med 383(14):1389\u20131391. https:\/\/doi.org\/10.1056\/NEJMc2016395","journal-title":"N Engl J Med"},{"key":"8952_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13005","author":"M Kaul","year":"2021","unstructured":"Kaul M, End P, Cabanski M et al (2021) Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. https:\/\/doi.org\/10.1111\/cts.13005","journal-title":"Clin Transl Sci"},{"issue":"16","key":"8952_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s40265-020-01387-9","volume":"80","author":"AM Gim\u00e9nez-Arnau","year":"2020","unstructured":"Gim\u00e9nez-Arnau AM, Salman A (2020) Targeted therapy for chronic spontaneous urticaria: rationale and recent progress. Drugs 80(16):1617\u20131634. https:\/\/doi.org\/10.1007\/s40265-020-01387-9","journal-title":"Drugs"},{"key":"8952_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-016-0139-2","volume":"7","author":"E Kocat\u00fcrk","year":"2017","unstructured":"Kocat\u00fcrk E, Maurer M, Metz M, Grattan C (2017) Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy 7:1. https:\/\/doi.org\/10.1186\/s13601-016-0139-2","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"8952_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jaci.2020.03.005","volume":"145","author":"S Altrichter","year":"2020","unstructured":"Altrichter S, Frischbutter S, Fok JS et al (2020) The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol 145(6):1510\u20131516. https:\/\/doi.org\/10.1016\/j.jaci.2020.03.005","journal-title":"J Allergy Clin Immunol"},{"key":"8952_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13223-019-0372-z","volume":"15","author":"CJ Bansal","year":"2019","unstructured":"Bansal CJ, Bansal AS (2019) Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol 15:56. https:\/\/doi.org\/10.1186\/s13223-019-0372-z","journal-title":"Allergy Asthma Clin Immunol"},{"key":"8952_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","volume":"10","author":"SJ Bracken","year":"2019","unstructured":"Bracken SJ, Abraham S, MacLeod AS (2019) Autoimmune theories of chronic spontaneous urticaria. Front Immunol 10:627. https:\/\/doi.org\/10.3389\/fimmu.2019.00627","journal-title":"Front Immunol"},{"issue":"22","key":"8952_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","volume":"328","author":"M Hide","year":"1993","unstructured":"Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW (1993) Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328(22):1599\u20131604. https:\/\/doi.org\/10.1056\/NEJM199306033282204","journal-title":"N Engl J Med"},{"issue":"6","key":"8952_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2222.1991.tb03198.x","volume":"21","author":"CE Grattan","year":"1991","unstructured":"Grattan CE, Francis DM, Hide M, Greaves MW (1991) Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 21(6):695\u2013704. https:\/\/doi.org\/10.1111\/j.1365-2222.1991.tb03198.x","journal-title":"Clin Exp Allergy"},{"key":"8952_CR23","unstructured":"Dabija D, Tadi P (2021) Chronic urticaria. In: StatPearls. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32310370. Accessed 29 Sept 2021"},{"key":"8952_CR24","doi-asserted-by":"publisher","first-page":"486974","DOI":"10.1155\/2015\/486974","volume":"2015","author":"H Gu","year":"2015","unstructured":"Gu H, Li L, Gu M, Zhang G (2015) Association between Helicobacter pylori infection and chronic urticaria: a meta-analysis. Gastroenterol Res Pract 2015:486974. https:\/\/doi.org\/10.1155\/2015\/486974","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"8952_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0301-0546(02)79133-7","volume":"30","author":"P Gaig","year":"2002","unstructured":"Gaig P, Garc\u00eda-Ortega P, Enrique E, Papo M, Quer JC, Richard C (2002) Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. Allergol Immunopathol 30(5):255\u2013258. https:\/\/doi.org\/10.1016\/s0301-0546(02)79133-7","journal-title":"Allergol Immunopathol"},{"issue":"2","key":"8952_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.alit.2017.09.003","volume":"67","author":"Y Yanase","year":"2018","unstructured":"Yanase Y, Takahagi S, Hide M (2018) Chronic spontaneous urticaria and the extrinsic coagulation system. Allergol Int 67(2):191\u2013194. https:\/\/doi.org\/10.1016\/j.alit.2017.09.003","journal-title":"Allergol Int"},{"issue":"2","key":"8952_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000155748","volume":"148","author":"M Cugno","year":"2009","unstructured":"Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R (2009) Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 148(2):170\u2013174. https:\/\/doi.org\/10.1159\/000155748","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"8952_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1067\/mai.2002.123236","volume":"109","author":"S Ying","year":"2002","unstructured":"Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP (2002) TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 109(4):694\u2013700. https:\/\/doi.org\/10.1067\/mai.2002.123236","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8952_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00000372-199602000-00008","volume":"18","author":"M Toyoda","year":"1996","unstructured":"Toyoda M, Maruyama T, Morohashi M, Bhawan J (1996) Free eosinophil granules in urticaria: a correlation with the duration of wheals. Am J Dermatopathol 18(1):49\u201357. https:\/\/doi.org\/10.1097\/00000372-199602000-00008","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"8952_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1872213X13666190328164931","volume":"13","author":"KL Hon","year":"2019","unstructured":"Hon KL, Leung AKC, Ng WGG, Loo SK (2019) Chronic urticaria: an overview of treatment and recent patents. Recent Pat Inflamm Allergy Drug Discov 13(1):27\u201337. https:\/\/doi.org\/10.2174\/1872213X13666190328164931","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"4","key":"8952_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1398-9995.2009.02325.x","volume":"65","author":"MK Church","year":"2010","unstructured":"Church MK, Maurer M, Simons FER et al (2010) Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 65(4):459\u2013466. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.02325.x","journal-title":"Allergy"},{"issue":"2","key":"8952_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jaip.2020.08.055","volume":"9","author":"P Phinyo","year":"2021","unstructured":"Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M (2021) Comparative efficacy and acceptability of licensed dose second-generation antihistamines in chronic spontaneous urticaria: a network meta-analysis. J Allergy Clin Immunol Pract 9(2):956-970.e57. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.055","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"8952_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","volume":"125","author":"M Staevska","year":"2010","unstructured":"Staevska M, Popov TA, Kralimarkova T et al (2010) The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125(3):676\u2013682. https:\/\/doi.org\/10.1016\/j.jaci.2009.11.047","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8952_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jaci.2008.12.008","volume":"123","author":"F Siebenhaar","year":"2009","unstructured":"Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M (2009) High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 123(3):672\u2013679. https:\/\/doi.org\/10.1016\/j.jaci.2008.12.008","journal-title":"J Allergy Clin Immunol"},{"key":"8952_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-017-0141-3","author":"MT van den Elzen","year":"2017","unstructured":"van den Elzen MT, van Os-Medendorp H, van den Brink I et al (2017) Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy. https:\/\/doi.org\/10.1186\/s13601-017-0141-3","journal-title":"Clin Transl Allergy."},{"issue":"3","key":"8952_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2500\/aap.2017.38.4050","volume":"38","author":"AS Nayak","year":"2017","unstructured":"Nayak AS, Berger WE, LaForce CF et al (2017) Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc 38(3):222\u2013230. https:\/\/doi.org\/10.2500\/aap.2017.38.4050","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"8952_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1365-2125.2006.02810.x","volume":"63","author":"S Gupta","year":"2007","unstructured":"Gupta S, Khalilieh S, Kantesaria B, Banfield C (2007) Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 63(5):534\u2013540. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02810.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"8952_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1399-3038.2004.00167.x","volume":"15","author":"EO Meltzer","year":"2004","unstructured":"Meltzer EO, Scheinmann P, Rosado Pinto JE et al (2004) Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis\u2014a pooled analysis of three studies. Pediatr Allergy Immunol 15(3):253\u2013260. https:\/\/doi.org\/10.1111\/j.1399-3038.2004.00167.x","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"8952_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1159\/000321181","volume":"155","author":"AN Pampura","year":"2011","unstructured":"Pampura AN, Papadopoulos NG, Spi\u010d\u00e1k V, Kurzawa R (2011) Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 155(4):367\u2013378. https:\/\/doi.org\/10.1159\/000321181","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"8952_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/pai.12555","volume":"27","author":"Z Nov\u00e1k","year":"2016","unstructured":"Nov\u00e1k Z, Y\u00e1\u00f1ez A, Kiss I et al (2016) Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol 27(5):493\u2013498. https:\/\/doi.org\/10.1111\/pai.12555","journal-title":"Pediatr Allergy Immunol"},{"issue":"4","key":"8952_CR41","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","volume":"55","author":"GA Vena","year":"2006","unstructured":"Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P, Neo-I-30 Study Group (2006) Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 55(4):705\u2013709. https:\/\/doi.org\/10.1016\/j.jaad.2006.04.078","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"8952_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2249.2008.03693.x","volume":"153","author":"SJ Deacock","year":"2008","unstructured":"Deacock SJ (2008) An approach to the patient with urticaria. Clin Exp Immunol 153(2):151\u2013161. https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03693.x","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"8952_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/all.14547","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache I, Rocha C, Pereira A et al (2021) Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy 76(1):59\u201370. https:\/\/doi.org\/10.1111\/all.14547","journal-title":"Allergy"},{"issue":"3","key":"8952_CR44","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/jid.2014.512","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M et al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 135(3):925. https:\/\/doi.org\/10.1038\/jid.2014.512","journal-title":"J Invest Dermatol"},{"issue":"10","key":"8952_CR45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10):924\u2013935. https:\/\/doi.org\/10.1056\/NEJMoa1215372","journal-title":"N Engl J Med"},{"issue":"3","key":"8952_CR46","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","volume":"141","author":"M Maurer","year":"2018","unstructured":"Maurer M, Kaplan A, Ros\u00e9n K et al (2018) The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria. J Allergy Clin Immunol 141(3):1138-1139.e7. https:\/\/doi.org\/10.1016\/j.jaci.2017.10.018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8952_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.aller.2020.03.011","volume":"48","author":"M Ocak","year":"2020","unstructured":"Ocak M, Soyer O, Buyuktiryaki B, Sekerel BE, Sahiner UM (2020) Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety. Allergol Immunopathol 48(4):368\u2013373. https:\/\/doi.org\/10.1016\/j.aller.2020.03.011","journal-title":"Allergol Immunopathol"},{"issue":"11","key":"8952_CR48","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/cea.12400","volume":"44","author":"JP Arm","year":"2014","unstructured":"Arm JP, Bottoli I, Skerjanec A et al (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44(11):1371\u20131385. https:\/\/doi.org\/10.1111\/cea.12400","journal-title":"Clin Exp Allergy"},{"issue":"14","key":"8952_CR49","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","volume":"381","author":"M Maurer","year":"2019","unstructured":"Maurer M, Gim\u00e9nez-Arnau AM, Sussman G et al (2019) Ligelizumab for chronic spontaneous urticaria. N Engl J Med 381(14):1321\u20131332. https:\/\/doi.org\/10.1056\/NEJMoa1900408","journal-title":"N Engl J Med"},{"key":"8952_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/all.15175","author":"M Maurer","year":"2021","unstructured":"Maurer M, Gim\u00e9nez-Arnau A, Bernstein JA et al (2022) Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study. Allergy. https:\/\/doi.org\/10.1111\/all.15175","journal-title":"Allergy"},{"issue":"1","key":"8952_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA (2020) Mechanisms of dupilumab. Clin Exp Allergy 50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"8952_CR52","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","volume":"7","author":"JK Lee","year":"2019","unstructured":"Lee JK, Simpson RS (2019) Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract 7(5):1659-1661.e1. https:\/\/doi.org\/10.1016\/j.jaip.2018.11.018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"8952_CR53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.anai.2020.06.034","volume":"126","author":"B Goodman","year":"2021","unstructured":"Goodman B, Jariwala S (2021) Dupilumab as a novel therapy to treat adrenergic urticaria. Ann Allergy Asthma Immunol 126(2):205\u2013206. https:\/\/doi.org\/10.1016\/j.anai.2020.06.034","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8952_CR54","unstructured":"Hom S, Pisano M (2017) Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. P T 42(9):564\u2013568. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28890642. Accessed 29 Sept 2021"},{"issue":"20","key":"8952_CR55","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D et al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376(20):1921\u20131932. https:\/\/doi.org\/10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"issue":"13","key":"8952_CR56","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198\u20131207. https:\/\/doi.org\/10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"issue":"6","key":"8952_CR57","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","volume":"146","author":"F Roufosse","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME et al (2020) Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 146(6):1397\u20131405. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.037","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"8952_CR58","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.187.8.1235","volume":"187","author":"D Hata","year":"1998","unstructured":"Hata D, Kawakami Y, Inagaki N et al (1998) Involvement of Bruton\u2019s tyrosine kinase in Fc\u03b5RI-dependent mast cell degranulation and cytokine production. J Exp Med 187(8):1235\u20131247. https:\/\/doi.org\/10.1084\/jem.187.8.1235","journal-title":"J Exp Med"},{"key":"8952_CR59","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3968885","author":"M Maurer","year":"2021","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A et al (2021) Remibrutinib (LOU064) versus placebo in patients with chronic spontaneous urticaria: a randomised, double-blind, phase 2b dose-finding study. SSRN Electron J. https:\/\/doi.org\/10.2139\/ssrn.3968885","journal-title":"SSRN Electron J"},{"issue":"11","key":"8952_CR60","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","volume":"27","author":"M Metz","year":"2021","unstructured":"Metz M, Sussman G, Gagnon R et al (2021) Fenebrutinib in H antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med 27(11):1961\u20131969. https:\/\/doi.org\/10.1038\/s41591-021-01537-w","journal-title":"Nat Med"},{"issue":"2 Pt 1","key":"8952_CR61","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/s0091-6749(99)70506-3","volume":"103","author":"B Hermes","year":"1999","unstructured":"Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM (1999) Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 103(2 Pt 1):307\u2013314. https:\/\/doi.org\/10.1016\/s0091-6749(99)70506-3","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8952_CR62","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jaad.2009.10.043","volume":"64","author":"LH Wilson","year":"2011","unstructured":"Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL (2011) Treatment of refractory chronic urticaria with tumor necrosis factor\u2013alfa inhibitors. J Am Acad Dermatol 64(6):1221\u20131222. https:\/\/doi.org\/10.1016\/j.jaad.2009.10.043","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"8952_CR63","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.10947","volume":"48","author":"GJ Silverman","year":"2003","unstructured":"Silverman GJ, Weisman S (2003) Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48(6):1484\u20131492. https:\/\/doi.org\/10.1002\/art.10947","journal-title":"Arthritis Rheum"},{"issue":"4","key":"8952_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000487402","volume":"31","author":"A Combalia","year":"2018","unstructured":"Combalia A, Losno RA, Prieto-Gonz\u00e1lez S, Mascar\u00f3 JM (2018) Rituximab in refractory chronic spontaneous urticaria: an encouraging therapeutic approach. Skin Pharmacol Physiol 31(4):184\u2013187. https:\/\/doi.org\/10.1159\/000487402","journal-title":"Skin Pharmacol Physiol"},{"issue":"7","key":"8952_CR65","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/eji.201041195","volume":"41","author":"M Kitajima","year":"2011","unstructured":"Kitajima M, Lee HC, Nakayama T, Ziegler SF (2011) TSLP enhances the function of helper type 2 cells. Eur J Immunol 41(7):1862\u20131871. https:\/\/doi.org\/10.1002\/eji.201041195","journal-title":"Eur J Immunol"},{"issue":"1","key":"8952_CR66","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2011.08.031","volume":"129","author":"A Shikotra","year":"2012","unstructured":"Shikotra A, Choy DF, Ohri CM et al (2012) Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 129(1):104-111.e1\u2212e9. https:\/\/doi.org\/10.1016\/j.jaci.2011.08.031","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"8952_CR67","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/cea.13616","volume":"50","author":"DA Sabag","year":"2020","unstructured":"Sabag DA, Matanes L, Bejar J et al (2020) Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy 50(7):799\u2013804. https:\/\/doi.org\/10.1111\/cea.13616","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"8952_CR68","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jaip.2018.04.003","volume":"6","author":"M Ferrer","year":"2018","unstructured":"Ferrer M, Gim\u00e9nez-Arnau A, Saldana D et al (2018) Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis. J Allergy Clin Immunol Pract 6(4):1191-1197.e5. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.003","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"8952_CR69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/all.13345","volume":"73","author":"R Ertas","year":"2018","unstructured":"Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M (2018) The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 73(3):705\u2013712. https:\/\/doi.org\/10.1111\/all.13345","journal-title":"Allergy"},{"issue":"6","key":"8952_CR70","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","volume":"140","author":"R Ertas","year":"2017","unstructured":"Ertas R, Ozyurt K, Ozlu E et al (2017) Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol 140(6):1749\u20131751. https:\/\/doi.org\/10.1016\/j.jaci.2017.08.007","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8952_CR71","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.jaci.2018.02.021","volume":"141","author":"G Deza","year":"2018","unstructured":"Deza G, Bertol\u00edn-Colilla M, S\u00e1nchez S et al (2018) Basophil Fc\u025bRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol 141(6):2313-2316.e1. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.021","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"8952_CR72","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2217\/imt-2020-0088","volume":"12","author":"T Grieco","year":"2020","unstructured":"Grieco T, Dies L, Sernicola A et al (2020) Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment. Immunotherapy 12(16):1173\u20131181. https:\/\/doi.org\/10.2217\/imt-2020-0088","journal-title":"Immunotherapy"},{"issue":"7","key":"8952_CR73","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL, AMA Manual of Style Committee (2021) Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA 326(7):621\u2013627. https:\/\/doi.org\/10.1001\/jama.2021.13304","journal-title":"JAMA"},{"issue":"5","key":"8952_CR74","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B et al (2019) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol 180(5):1069\u20131076. https:\/\/doi.org\/10.1111\/bjd.16776","journal-title":"Br J Dermatol"},{"issue":"11","key":"8952_CR75","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1016\/j.jaip.2021.07.013","volume":"9","author":"SJ Szefler","year":"2021","unstructured":"Szefler SJ, Jerschow E, Yoo B et al (2021) Response to omalizumab in black and white patients with allergic asthma. J Allergy Clin Immunol Pract 9(11):4021\u20134028. https:\/\/doi.org\/10.1016\/j.jaip.2021.07.013","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08952-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T10:18:38Z","timestamp":1668766718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08952-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":75,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8952"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08952-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"23 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}